» Articles » PMID: 28615429

Diagnostic Algorithm for Relapsing Acquired Demyelinating Syndromes in Children

Overview
Journal Neurology
Specialty Neurology
Date 2017 Jun 16
PMID 28615429
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To establish whether children with relapsing acquired demyelinating syndromes (RDS) and myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) show distinctive clinical and radiologic features and to generate a diagnostic algorithm for the main RDS for clinical use.

Methods: A panel reviewed the clinical characteristics, MOG-Ab and aquaporin-4 (AQP4) Ab, intrathecal oligoclonal bands, and Epstein-Barr virus serology results of 110 children with RDS. A neuroradiologist blinded to the diagnosis scored the MRI scans. Clinical, radiologic, and serologic tests results were compared.

Results: The findings showed that 56.4% of children were diagnosed with multiple sclerosis (MS), 25.4% with neuromyelitis optica spectrum disorder (NMOSD), 12.7% with multiphasic disseminated encephalomyelitis (MDEM), and 5.5% with relapsing optic neuritis (RON). Blinded analysis defined baseline MRI as typical of MS in 93.5% of children with MS. Acute disseminated encephalomyelitis presentation was seen only in the non-MS group. Of NMOSD cases, 30.7% were AQP4-Ab positive. MOG-Ab were found in 83.3% of AQP4-Ab-negative NMOSD, 100% of MDEM, and 33.3% of RON. Children with MOG-Ab were younger, were less likely to present with area postrema syndrome, and had lower disability, longer time to relapse, and more cerebellar peduncle lesions than children with AQP4-Ab NMOSD. A diagnostic algorithm applicable to any episode of CNS demyelination leads to 4 main phenotypes: MS, AQP4-Ab NMOSD, MOG-Ab-associated disease, and antibody-negative RDS.

Conclusions: Children with MS and AQP4-Ab NMOSD showed features typical of adult cases. Because MOG-Ab-positive children showed notable and distinctive clinical and MRI features, they were grouped into a unified phenotype (MOG-Ab-associated disease), included in a new diagnostic algorithm.

Citing Articles

The influence of MOGAD on diagnosis of multiple sclerosis using MRI.

Geraldes R, Arrambide G, Banwell B, Rovira A, Cortese R, Lassmann H Nat Rev Neurol. 2024; 20(10):620-635.

PMID: 39227463 DOI: 10.1038/s41582-024-01005-2.


Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children.

Varley J, Champsas D, Prossor T, Pontillo G, Abdel-Mannan O, Khaleeli Z Neurology. 2024; 103(1):e209321.

PMID: 38870448 PMC: 11244737. DOI: 10.1212/WNL.0000000000209321.


Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management.

Gklinos P, Dobson R Antibodies (Basel). 2024; 13(2).

PMID: 38804311 PMC: 11130828. DOI: 10.3390/antib13020043.


Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.

Cacciaguerra L, Abdel-Mannan O, Champsas D, Mankad K, Krecke K, Chen J Neurology. 2024; 102(10):e209303.

PMID: 38710000 PMC: 11177594. DOI: 10.1212/WNL.0000000000209303.


Postacute Sequelae of SARS-CoV-2 in Children.

Rao S, Gross R, Mohandas S, Stein C, Case A, Dreyer B Pediatrics. 2024; 153(3).

PMID: 38321938 PMC: 10904902. DOI: 10.1542/peds.2023-062570.